By Scientia Professor Gregory John Dore

Journal articles

Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV, 2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651

Martinello M; Solomon SS; Terrault NA; Dore GJ, 2023, 'Hepatitis C', Lancet, 402, pp. 1085 - 1096, http://dx.doi.org/10.1016/S0140-6736(23)01320-X

Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J, 2023, 'A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644, http://dx.doi.org/10.1016/j.jhep.2023.04.019

Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M, 2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168

Feld JJ; Bruneau J; Dore GJ; Ghany MG; Hansen B; Sulkowski M; Thomas DL, 2023, 'Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations', Clinical Infectious Diseases, 77, pp. S262 - S269, http://dx.doi.org/10.1093/cid/ciad362

Koopsen J; Matthews G; Rockstroh J; Applegate TL; Bhagani S; Rauch A; Grebely J; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard M; Dore GJ; Schinkel J; van der Valk M; Adams T; Amjad S; Appelhans C; Becker B; Bouchard R; Braun D; Bruelisauer C; Calcagnile S; Carroll A; Cerocchi O; Chronister K; Cordes C; Dore G; Evans F; Fedele S; Ferguson C; Fraser C; Ganase B; Gane E; George V; Gerlach C; Gilleece Y; Gilliver R; Grube C; Gustafson J; Haas A; Hagenauer M; Harris M; Helder J; Hirter D; Hull M; Katz S; Kim A; Kotsoros B; Lacalamita M; Lindergard G; Lutz T; Macabodbod L; Manz M; Marks P; Messina P; Mohrmann K; Monnich C; Moon J; Moriggia A; Morris G; Morrish T; Nelson M; Oliver V; Patterson J; Peters M; Petoumenos K; Porretta H; Raymode P; Read P; Reece S; Saidi A; Sasadeusz J; Scherler P; Schröder R; Selfridge M; Sevehon A; Shaw D; Sulkowski M; Tamaddoni M; Thunder O; Thurnheer MC; Tu E; Ustianowski A; Witele E, 2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8

Cysique LA; Jakabek D; Bracken SG; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Staats Pires A; Darley DR; Byrne A; Phetsouphanh C; Kelleher A; Dore GJ; Matthews GV; Guillemin GJ; Brew BJ, 2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352, http://dx.doi.org/10.1002/acn3.51825

Price O; Maher L; Dietze PM; Bruno R; Crawford S; Sutherland R; Salom C; Dore GJ; Peacock A, 2023, 'COVID-19 vaccine attitudes and facilitators among people in Australia who inject drugs', Drug and Alcohol Review, 42, pp. 1066 - 1077, http://dx.doi.org/10.1111/dar.13621

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', Lancet Regional Health Western Pacific, 36, pp. 100750, http://dx.doi.org/10.1016/j.lanwpc.2023.100750

Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ, 2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529, http://dx.doi.org/10.1111/jvh.13824

Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J; Dore G; Crawford S; Swan T; Byrne J; Coordinating Centre—Amanda Erratt ML; Marks P; Shaw I; Siriragavan S; Quiene S; Petoumenos K; Schmid P; Castro E; Moriggia A; Daulouede JP; Fraser C; Feld J; Gane E; Matthews G; Kronborg I; Shaw D; Norton B; Thurnheer MC; Weltman M; Read P; Dillon J; Kessler S; Knapp C; Oprandi L; Messina P; Pantic M; Le Cam M; Maitre C; Andreassen J; Melkeraaen I; Tollefsen MM; Pagarigan H; Milne R; Mason K; Kaznowski D; Zou L; Bouchard R; Kotsoros B; Muir M; Milloy J; Oliver V; Noonan T; Sevehon A; Hazelwood S; Hall M; Hagenauer M; Liddle R; Ferguson C; Agyemang L; Patel H; Soloway I; Cerocchi O; Lacalamita M; Fragomeli V; Gilliver R; Lothian R; Cleary S; Johnston L; Middleton S; D'Amico R; McGovern B; Anderson J; Zhong Z; Keane F; Tatsch F; Brainard D; McHutchison J, 2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892, http://dx.doi.org/10.1016/j.jval.2022.12.016

Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020

Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J, 2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', Lancet Global Health, 11, pp. e659 - e672, http://dx.doi.org/10.1016/S2214-109X(23)00057-8

Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L, 2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', Lancet Global Health, 11, pp. e673 - e683, http://dx.doi.org/10.1016/S2214-109X(23)00058-X

Iversen J; Wand H; McManus H; Dore GJ; Maher L, 2023, 'Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies', Addiction, 118, pp. 901 - 911, http://dx.doi.org/10.1111/add.16113

Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Hayllar J; Grebely J; Marshall AD, 2023, '“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103998

Carson J; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125

Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P, 2023, 'Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103982

Grebely J; Markus C; Causer LM; Silk D; Comben S; Lloyd AR; Martinez M; Cunningham EB; O'Flynn M; Dore GJ; Matthews S, 2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7

Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791

Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P, 2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469

Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011

Schiavone B; Dore GJ; Stone E; Matthews GV; Darley DR, 2023, 'An update on long COVID and its management', Medicine Today, 24, pp. 37 - 43

Jessica HB; Carson J; Scott M; Patricia C; Nelson R; Helen VG; Phillip R; Hanson J; Robert M; Matthews G; Dore GJ; Martinello M, 2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803

Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761

Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009

Bin Usman Shah SH; Valerio H; Hajarizadeh B; Alavi M; Matthews G; Dore G, 2023, 'FRI-169 Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake', Journal of Hepatology, 78, pp. s910, http://dx.doi.org/10.1016/s0168-8278(23)02932-x

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, 2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, pp. 1032911, http://dx.doi.org/10.3389/fimmu.2022.1032911

Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876

Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246

Lazarus JV; Romero D; Kopka CJ; Karim SA; Abu-Raddad LJ; Almeida G; Baptista-Leite R; Barocas JA; Barreto ML; Bar-Yam Y; Bassat Q; Batista C; Bazilian M; Chiou ST; del Rio C; Dore GJ; Gao GF; Gostin LO; Hellard M; Jimenez JL; Kang G; Lee N; Matičič M; McKee M; Nsanzimana S; Oliu-Barton M; Pradelski B; Pyzik O; Rabin K; Raina S; Rashid SF; Rathe M; Saenz R; Singh S; Trock-Hempler M; Villapol S; Yap P; Binagwaho A; Kamarulzaman A; El-Mohandes A; Barreto M; Abdulla S; Addleman S; Aghayeva G; Agius R; Ahmed M; Ramy MA; Aide P; Aleman S; Alfred JP; Ali S; Aliaga J; Aloudat T; Alqahtani SA; Al-Salman J; Amuasi JH; Agrawal A; Anwar W; Araujo-Jorge T; Artaza O; Asadi L; Awuku Y; Baker M; Barberia L; Bascolo E; Belcher P; Bell L; Benzaken A; Bergholtz E; Bhadelia N; Bhan A; Bilodeau S; Bitrán R; Bluyssen P; Bosman A; Bozza FA; Brinkmann MM; Brown A; Mellado B; Bukusi E; Bullen C; Buonanno G; Burgess R; Butler M; Byakika-Kibwika P; Cabieses B; Carlsson G; Cascini F; Chabala C; Chakroun M; Cheng KK; Chetty A; Chumachenko D; Consalves G; Conway Morris A; Cordie A; Corrah T; Crabtree-Ramírez B; Dashdorj N; Davidovitch N, 2022, 'A multinational Delphi consensus to end the COVID-19 public health threat', Nature, 611, pp. 332 - 345, http://dx.doi.org/10.1038/s41586-022-05398-2

Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J, 2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Kaldor J; Dore G; Sorrell T; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Sultan R; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272

Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA, 2022, 'Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review', Clinical Pharmacokinetics, 61, pp. 1331 - 1343, http://dx.doi.org/10.1007/s40262-022-01170-x

Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', Jhep Reports, 4, http://dx.doi.org/10.1016/j.jhepr.2022.100552

Catlett B; Hajarizadeh B; Cunningham E; Wolfson-Stofko B; Wheeler A; Khandaker-Hussain B; Feld JJ; Martró E; Chevaliez S; Pawlotsky JM; Bharat C; Cunningham PH; Dore GJ; Applegate T; Grebely J, 2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049

Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M, 2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719

Grebely J; Dore GJ; Altice FL; Conway B; Litwin AH; Norton BL; Dalgard O; Gane EJ; Shibolet O; Nahass R; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Hwang P; Asante-Appiah E; Haber BA; Barr E; Robertson MN; Platt H, 2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, 175, pp. 1221 - 1229, http://dx.doi.org/10.7326/M21-4119

Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746

Catlett B; Starr M; Machalek DA; Danwilai T; Palmer M; Kelly A; Kaldor J; Dore GJ; Darley D; Matthews G; Cunningham PH, 2022, 'Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection: SARS-CoV-2 detection from dried blood spots', Journal of Clinical Virology Plus, 2, http://dx.doi.org/10.1016/j.jcvp.2022.100093

Wheeler A; Valerio H; Cunningham EB; Martinello M; Barocas JA; Colledge-Frisby S; Treloar C; Amin J; Henderson C; Read P; Matthews GV; Dunlop AJ; Gorton C; Hayllar J; Alavi M; Murray C; Marks P; Silk D; Degenhardt L; Dore GJ; Grebely J, 2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543

Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705

Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J, 2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555

Lockart I; Yeo MGH; Hajarizadeh B; Dore G; Danta M; Abe K; Carrat F; Lusivika-Nzinga C; Degasperi E; Di Marco V; Hou J; Howell J; Janjua NZ; Wong S; Kumada T; Lleo A; Persico M; Lok AS; Wei L; Yang M; Nabatchikova E; Nguyen MH; Antonio Pineda J; Reig M; Shiha G; Yu ML; Tsai PC, 2022, 'HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis', Hepatology, 76, pp. 139 - 154, http://dx.doi.org/10.1002/hep.32341

Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV, 2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', Lancet HIV, 9, pp. e414 - e427, http://dx.doi.org/10.1016/S2352-3018(22)00077-7

Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Christmass M; Cock V; Burns C; Henderson C; Wiseman V; Dore GJ; Grebely J, 2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, 235, http://dx.doi.org/10.1016/j.drugalcdep.2022.109438

Lazarus JV; Picchio CA; Byrne CJ; Crespo J; Colombo M; Cooke GS; Dore GJ; Grebely J; Ward JW; Dillon JF, 2022, 'A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination', Seminars in Liver Disease, 42, pp. 159 - 172, http://dx.doi.org/10.1055/a-1777-6112

Back to profile page